• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Ultragenyx Pharmaceutical Inc.

    2/14/23 10:10:46 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RARE alert in real time by email
    SC 13G 1 p23-0583sc13g.htm ULTRAGENYX PHARMACEUTICAL INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Ultragenyx Pharmaceutical Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    90400B108

    (CUSIP Number)
     

    December 31, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 90400D10813GPage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,966,915 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,966,915 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,966,915 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 90400D10813GPage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,966,915 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,966,915 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,966,915 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 90400D10813GPage 4 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Ultragenyx Pharmaceutical Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 60 Leveroni Court, Novato, California 94949.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

     

    CUSIP No. 90400D10813GPage 5 of 8 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      90400D108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _______________________________

       

     

    Item 4. OWNERSHIP.
         
        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 70,105,654 Shares outstanding as of October 28, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 3, 2022.

     

     

    CUSIP No. 90400D10813GPage 6 of 8 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 90400D10813GPage 7 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 14, 2023

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

     

    CUSIP No. 90400D10813GPage 8 of 8 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATE: February 14, 2023

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

    Get the next $RARE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RARE

    DatePrice TargetRatingAnalyst
    6/6/2024$56.00 → $67.00Neutral → Buy
    Goldman
    4/22/2024$77.00Outperform
    RBC Capital Mkts
    12/8/2023$72.00Overweight
    Wells Fargo
    6/14/2023$96.00Outperform
    Credit Suisse
    6/6/2023$60.00 → $80.00In-line → Outperform
    Evercore ISI
    4/26/2023$114.00Overweight
    Cantor Fitzgerald
    1/18/2023$90.00Buy
    Canaccord Genuity
    12/30/2022$82.00Buy
    H.C. Wainwright
    More analyst ratings

    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and Chief Medical Officer Crombez Eric sold $28,901 worth of shares (762 units at $37.93), decreasing direct ownership by 0.55% to 71,530 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      5/5/25 7:18:48 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Horn Howard sold $72,114 worth of shares (1,785 units at $40.40), decreasing direct ownership by 2% to 106,169 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/10/25 12:53:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBO & EVP Kassberg Thomas Richard was granted 18,443 shares, sold $253,779 worth of shares (6,028 units at $42.10) and covered exercise/tax liability with 508 shares, increasing direct ownership by 5% to 264,730 units (SEC Form 4)

      4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

      3/4/25 8:19:57 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

      NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,

      7/12/23 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

      NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx's chief medical officer for gene therapy and inborn errors of metabolism. "Eric has extensive expertise in the development and execution of clinical development programs for rare genetic disorders and has been a driving force for our entire gene therapy pipeline," said Emil D. Kakkis, M.D., Ph.D., chief executive of

      3/14/23 8:30:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

      NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company's Board of Directors. Dr. Ray will serve on the Board's Research and Development Committee. "Dr. Ray brings to our Board of Directors decades of global experience as a physician researcher, biopharmaceutical executive, and champion for patient access to innovative treatments," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "His expertise

      4/22/22 8:00:00 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ultragenyx Pharma upgraded by Goldman with a new price target

      Goldman upgraded Ultragenyx Pharma from Neutral to Buy and set a new price target of $67.00 from $56.00 previously

      6/6/24 7:19:22 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ultragenyx Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ultragenyx Pharma with a rating of Outperform and set a new price target of $77.00

      4/22/24 7:43:41 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Ultragenyx Pharma with a new price target

      Wells Fargo initiated coverage of Ultragenyx Pharma with a rating of Overweight and set a new price target of $72.00

      12/8/23 7:56:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      11/14/24 6:42:29 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 10:03:02 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc. (Amendment)

      SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

      2/14/24 7:46:34 AM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

      NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed t

      5/7/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    Financials

    Live finance-specific insights

    See more
    • Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

      First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025 NOVATO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today

      5/6/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

      NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutica

      4/30/25 5:00:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

      2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. "We have created a ne

      2/13/25 4:01:00 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RARE
    SEC Filings

    See more
    • Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      5/6/25 4:10:49 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ultragenyx Pharmaceutical Inc.

      DEFA14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:01:02 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ultragenyx Pharmaceutical Inc.

      DEF 14A - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

      3/28/25 5:00:35 PM ET
      $RARE
      Biotechnology: Pharmaceutical Preparations
      Health Care